Status and phase
Conditions
Treatments
About
The purpose of this study is to establish the safety, toxicity, and tolerability of Difluoromethylornithine (DFMO) in combination with pembrolizumab in advanced/metastatic Non-Small Cell Lung Cancer (NSCLC). Researchers also want to investigate how effective DFMO is at treating patients with advanced/ metastatic NSCLC.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in situ cervical cancer.
Primary purpose
Allocation
Interventional model
Masking
45 participants in 2 patient groups
Loading...
Central trial contact
Anahid Aminpour
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal